Wnt, glucocorticoid and cellular prion protein cooperate to drive a mesenchymal phenotype with poor prognosis in colon cancer
Background The mesenchymal subtype of colorectal cancer (CRC), associated with poor prognosis, is characterized by abundant expression of the cellular prion protein $ PrP^{C} $, which represents a candidate therapeutic target. How $ PrP^{C} $ is induced in CRC remains elusive. This study aims to elucidate the signaling pathways governing $ PrP^{C} $ expression and to shed light on the gene regulatory networks linked to $ PrP^{C} $. Methods We performed in silico analyses on diverse datasets of in vitro, ex vivo and in vivo models of mouse CRC and patient cohorts. We mined ChIPseq studies and performed promoter analysis. CRC cell lines were manipulated through genetic and pharmacological approaches. We created mice combining conditional inactivation of Apc in intestinal epithelial cells and overexpression of the human prion protein gene PRNP. Bio-informatic analyses were carried out in two randomized control trials totalizing over 3000 CRC patients. Results In silico analyses combined with cell-based assays identified the Wnt-β-catenin and glucocorticoid pathways as upstream regulators of PRNP expression, with subtle differences between mouse and human. We uncover multiple feedback loops between $ PrP^{C} $ and these two pathways, which translate into an aggravation of CRC pathogenesis in mouse. In stage III CRC patients, the signature defined by PRNP-CTNNB1-NR3C1, encoding $ PrP^{C} $, β-catenin and the glucocorticoid receptor respectively, is overrepresented in the poor-prognosis, mesenchymal subtype and associates with reduced time to recurrence. Conclusions An unleashed $ PrP^{C} $-dependent vicious circle is pathognomonic of poor prognosis, mesenchymal CRC. Patients from this aggressive subtype of CRC may benefit from therapies targeting the PRNP-CTNNB1-NR3C1 axis..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:22 |
|---|---|
| Enthalten in: |
Journal of translational medicine - 22(2024), 1 vom: 08. Apr. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Mouillet-Richard, Sophie [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
Colon cancer |
|---|
| Anmerkungen: |
© The Author(s) 2024 |
|---|
| doi: |
10.1186/s12967-024-05164-0 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR055461689 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR055461689 | ||
| 003 | DE-627 | ||
| 005 | 20240409064754.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240409s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s12967-024-05164-0 |2 doi | |
| 035 | |a (DE-627)SPR055461689 | ||
| 035 | |a (SPR)s12967-024-05164-0-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q VZ |
| 100 | 1 | |a Mouillet-Richard, Sophie |e verfasserin |0 (orcid)0000-0002-8950-1949 |4 aut | |
| 245 | 1 | 0 | |a Wnt, glucocorticoid and cellular prion protein cooperate to drive a mesenchymal phenotype with poor prognosis in colon cancer |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © The Author(s) 2024 | ||
| 520 | |a Background The mesenchymal subtype of colorectal cancer (CRC), associated with poor prognosis, is characterized by abundant expression of the cellular prion protein $ PrP^{C} $, which represents a candidate therapeutic target. How $ PrP^{C} $ is induced in CRC remains elusive. This study aims to elucidate the signaling pathways governing $ PrP^{C} $ expression and to shed light on the gene regulatory networks linked to $ PrP^{C} $. Methods We performed in silico analyses on diverse datasets of in vitro, ex vivo and in vivo models of mouse CRC and patient cohorts. We mined ChIPseq studies and performed promoter analysis. CRC cell lines were manipulated through genetic and pharmacological approaches. We created mice combining conditional inactivation of Apc in intestinal epithelial cells and overexpression of the human prion protein gene PRNP. Bio-informatic analyses were carried out in two randomized control trials totalizing over 3000 CRC patients. Results In silico analyses combined with cell-based assays identified the Wnt-β-catenin and glucocorticoid pathways as upstream regulators of PRNP expression, with subtle differences between mouse and human. We uncover multiple feedback loops between $ PrP^{C} $ and these two pathways, which translate into an aggravation of CRC pathogenesis in mouse. In stage III CRC patients, the signature defined by PRNP-CTNNB1-NR3C1, encoding $ PrP^{C} $, β-catenin and the glucocorticoid receptor respectively, is overrepresented in the poor-prognosis, mesenchymal subtype and associates with reduced time to recurrence. Conclusions An unleashed $ PrP^{C} $-dependent vicious circle is pathognomonic of poor prognosis, mesenchymal CRC. Patients from this aggressive subtype of CRC may benefit from therapies targeting the PRNP-CTNNB1-NR3C1 axis. | ||
| 650 | 4 | |a Colon cancer |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Prion protein |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Wnt-β-catenin |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Glucocorticoid receptor |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Molecular classification |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Gougelet, Angélique |e verfasserin |4 aut | |
| 700 | 1 | |a Passet, Bruno |e verfasserin |4 aut | |
| 700 | 1 | |a Brochard, Camille |e verfasserin |4 aut | |
| 700 | 1 | |a Le Corre, Delphine |e verfasserin |4 aut | |
| 700 | 1 | |a Pitasi, Caterina Luana |e verfasserin |4 aut | |
| 700 | 1 | |a Joubel, Camille |e verfasserin |4 aut | |
| 700 | 1 | |a Sroussi, Marine |e verfasserin |4 aut | |
| 700 | 1 | |a Gallois, Claire |e verfasserin |4 aut | |
| 700 | 1 | |a Lavergne, Julien |e verfasserin |4 aut | |
| 700 | 1 | |a Castille, Johan |e verfasserin |4 aut | |
| 700 | 1 | |a Vilotte, Marthe |e verfasserin |4 aut | |
| 700 | 1 | |a Daniel-Carlier, Nathalie |e verfasserin |4 aut | |
| 700 | 1 | |a Pilati, Camilla |e verfasserin |4 aut | |
| 700 | 1 | |a de Reyniès, Aurélien |e verfasserin |4 aut | |
| 700 | 1 | |a Djouadi, Fatima |e verfasserin |4 aut | |
| 700 | 1 | |a Colnot, Sabine |e verfasserin |4 aut | |
| 700 | 1 | |a André, Thierry |e verfasserin |4 aut | |
| 700 | 1 | |a Taieb, Julien |e verfasserin |4 aut | |
| 700 | 1 | |a Vilotte, Jean-Luc |e verfasserin |4 aut | |
| 700 | 1 | |a Romagnolo, Béatrice |e verfasserin |4 aut | |
| 700 | 1 | |a Laurent-Puig, Pierre |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of translational medicine |d BioMed Central, 2003 |g 22(2024), 1 vom: 08. Apr. |w (DE-627)SPR028930886 |w (DE-600)2118570-0 |x 1479-5876 |7 nnns |
| 773 | 1 | 8 | |g volume:22 |g year:2024 |g number:1 |g day:08 |g month:04 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1186/s12967-024-05164-0 |m X:VERLAG |x 0 |z kostenfrei |3 Volltext |
| 912 | |a GBV_SPRINGER | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |d 22 |j 2024 |e 1 |b 08 |c 04 | ||